Focus on Adoptive T Cell Transfer Trials in Melanoma

Adoptive Cell Transfer (ACT) of Tumor-Infiltrating Lymphocytes (TIL) in combination with lymphodepletion has proven to be an effective treatment for metastatic melanoma patients, with an objective response rate in 50%–70% of the patients. It is based on the ex vivo expansion and activation of tumor-specific T lymphocytes extracted from the tumor and their administration back to the patient. Various TIL-ACT trials, which differ in their TIL generation procedures and patient preconditioning, have been reported. In the latest clinical studies, genetically engineered peripheral T cells were utilized instead of TIL. Further improvement of adoptive T cell transfer depends on new investigations which seek higher TIL quality, increased durable response rates, and aim to treat more patients. Simplifying this therapy may encourage cancer centers worldwide to adopt this promising technology. This paper focuses on the latest progress regarding adoptive T cell transfer, comparing the currently available protocols and discussing their advantages, disadvantages, and implication in the future.

• Publication year

  2010

• Venue

  Clinical and Developmental Immunology

• Publication date

  2010-12-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1155/2010/260267PMID 21234353PMCID 3018069
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients

  2010cited by this paper
• Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells

  2010cited by this paper
• Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

  2010cited by this paper
• Characterization of Genetically Modified T-Cell Receptors that Recognize the CEA:691-699 Peptide in the Context of HLA-A2.1 on Human Colorectal Cancer Cells

  2009cited by this paper
• The history and future of chemotherapy for melanoma.

  2009cited by this paper
• Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells

  2009cited by this paper
• Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

  2009influential reference
• Role of Chemotherapy in Hodgkin’s Lymphoma

  2009cited by this paper
• Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.

  2009influential reference
• Predicting and controlling the reactivity of immune cell populations against cancer

  2009cited by this paper
• Minimally Cultured or Selected Autologous Tumor-infiltrating Lymphocytes After a Lympho-depleting Chemotherapy Regimen in Metastatic Melanoma Patients

  2009influential reference
• The promise and potential pitfalls of chimeric antigen receptors.

  2009influential reference
• Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.

  2008cited by this paper
• Relationship of p53 Overexpression on Cancers and Recognition by Anti-p53 T Cell Receptor-Transduced T Cells

  2008cited by this paper
• IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.

  2008cited by this paper
• Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

  2008influential reference
• Cancer Statistics, 2008

  2008cited by this paper
• Minimally Cultured Tumor-infiltrating Lymphocytes Display Optimal Characteristics for Adoptive Cell Therapy

  2008cited by this paper
• Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions

  2008cited by this paper
• Next generation of immunotherapy for melanoma.

  2008cited by this paper
• Adoptive cell transfer therapy.

  2007cited by this paper
• Persistence of Tumor Infiltrating Lymphocytes in Adoptive Immunotherapy Correlates With Telomere Length

  2007cited by this paper
• Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells.

  2007cited by this paper
• Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?

  2006cited by this paper
• Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

  2006cited by this paper
• A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer

  2006cited by this paper
• Modulation by IL-2 of CD70 and CD27 Expression on CD8+ T Cells: Importance for the Therapeutic Effectiveness of Cell Transfer Immunotherapy1

  2006cited by this paper
• Adoptive cell therapy for metastatic melanoma patients: pre-clinical development at the Sheba Medical Center.

  2006cited by this paper
• Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes

  2006influential reference
• Cutaneous melanoma: available therapy for metastatic disease

  2006cited by this paper
• T Cell Retargeting with MHC Class I-Restricted Antibodies: The CD28 Costimulatory Domain Enhances Antigen-Specific Cytotoxicity and Cytokine Production1

  2005cited by this paper
• Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.

  2005cited by this paper
• Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

  2005cited by this paper
• Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy.

  2005cited by this paper
• Survival, Persistence, and Progressive Differentiation of Adoptively Transferred Tumor-Reactive T Cells Associated with Tumor Regression

  2005cited by this paper
• CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells

  2005cited by this paper
• Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

  2005cited by this paper
• Gene modification strategies to induce tumor immunity.

  2005cited by this paper
• Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.

  2005cited by this paper
• Telomere Length of Transferred Lymphocytes Correlates with In Vivo Persistence and Tumor Regression in Melanoma Patients Receiving Cell Transfer Therapy1

  2005cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• Management of cutaneous melanoma.

  2004cited by this paper
• Homeostasis of Naive and Memory CD4+ T Cells: IL-2 and IL-7 Differentially Regulate the Balance Between Proliferation and Fas-Mediated Apoptosis1

  2003cited by this paper
• Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.

  2003cited by this paper
• Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients

  2003cited by this paper
• Targeting tumours with genetically enhanced T lymphocytes

  2003cited by this paper
• Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells

  2002cited by this paper
• Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

  2002cited by this paper
• Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

  2002cited by this paper
• T cell homeostatic proliferation elicits effective antitumor autoimmunity.

  2002cited by this paper
• Metastatic melanoma: chemotherapy.

  2002cited by this paper
• Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.

  2002cited by this paper
• CD4+ T Cells Engrafted with a Recombinant Immunoreceptor Efficiently Lyse Target Cells in a MHC Antigen- and Fas-Independent Fashion1

  2001cited by this paper
• Progress in human tumour immunology and immunotherapy

  2001cited by this paper
• Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors.

  2000cited by this paper
• Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.

  1999cited by this paper
• Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis.

  1998cited by this paper
• Passive but not active CD8+ T cell-based immunotherapy interferes with liver tumor progression in a transgenic mouse model.

  1998cited by this paper
• Cutting Edge: Passive But Not Active CD8+ T Cell-Based Immunotherapy Interferes with Liver Tumor Progression in a Transgenic Mouse Model

  1998cited by this paper
• Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes

  1997cited by this paper
• Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.

  1994cited by this paper
• In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.

  1994cited by this paper
• Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.

  1993cited by this paper
• Erratum: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer (J Natl Cancer Inst (1993) 85 (622-632))

  1993cited by this paper
• Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens.

  1993cited by this paper
• Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.

  1993cited by this paper
• Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion.

  1992cited by this paper
• Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas.

  1992cited by this paper
• Common Expression of Melanoma Tumor-Associated Antigens Recognized by Human Tumor Infiltrating Lymphocytes: Analysis by Human Lymphocyte Antigen Restriction

  1991cited by this paper
• Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation.

  1991cited by this paper
• Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response.

  1991cited by this paper
• Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.

  1990influential reference
• Cancer statistics

  1989influential reference
• The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens.

  1989cited by this paper
• Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

  1989cited by this paper
• Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

  1988cited by this paper
• Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy.

  1987cited by this paper
• Studies of serum-free culture medium in the generation of lymphokine activated killer cells.

  1987cited by this paper
• High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings.

  1986cited by this paper
• Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

  1985cited by this paper
• Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

  1984cited by this paper
• Transfer Therapy Cancer Regression in Patients Receiving Cell Lymphocyte Clonotypes Correlates with Cutting Edge: Persistence of Transferred

  year unknowncited by this paper

• Improving cell reinfusion to enhance the efficacy of chimeric antigen receptor T-cell therapy and alleviate complications

  2024cites this paper
• Advances and prospects in tumor infiltrating lymphocyte therapy

  2024cites this paper
• Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?

  2022cites this paper
• Dauricine inhibits proliferation and promotes death of melanoma cells via inhibition of Src/STAT3 signaling

  2021cites this paper
• Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response

  2020influential citation
• Nanomedicine and macroscale materials in immuno-oncology.

  2019cites this paper
• T cell immunotherapy enhanced by designer biomaterials.

  2019cites this paper
• Structure-Guided T Cell Receptor Mutations that Alter Antigen Specificity, Cross-Reactivity, and Polyfunctional Phenotypes in Gene-Modified T Cells

  2019cites this paper
• Adoptive Cell Therapy for Melanoma

  2018cites this paper
• Adoptive cell transfer: new perspective treatment in veterinary oncology

  2018cites this paper
• Adoptive Cell Transfer: Is it a Promising Immunotherapy for Colorectal Cancer?

  2018cites this paper
• The curative potential of chimeric antigen receptor T-cell therapy for B-cell malignancies

  2017cites this paper
• T-Lymphocyte Homing: An Underappreciated yet Critical Hurdle for Successful Cancer Immunotherapy

  2017cites this paper
• HCV T Cell Receptor Chain Modifications to Enhance Expression, Pairing, and Antigen Recognition in T Cells for Adoptive Transfer

  2017cites this paper
• CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity

  2017cites this paper
• Improving adenovirus-based immunotherapies for treatment of solid tumors

  2017cites this paper
• Chitosan thermogels for local expansion and delivery of tumor-specific T lymphocytes towards enhanced cancer immunotherapies.

  2016influential citation
• Generation of tumor‐specific cytotoxic T‐lymphocytes from the peripheral blood of colorectal cancer patients for adoptive T‐cell transfer

  2015cites this paper
• Redox modulation of oxidatively induced DNA damage by ascorbate enhances melanoma cancer cell DNA damage formation & cell killing

  2015influential citation
• Immunology and Immunotherapy in Brain Tumors — Immune Failure and Potential Counteractions

  2015cites this paper
• Tumor-Infiltrating Lymphocyte Therapy: Addressing Prevailing Questions

  2015cites this paper
• Adoptive T-Cell Immunotherapy: Perfecting Self-Defenses

  2014cites this paper
• The Tumor Microenvironment as Target for New Cancer Therapies

  2014cites this paper
• Cell‐Based Biologic Therapy for the Treatment of Medical Diseases

  2014cites this paper
• Xenogene vaccination in the therapy of cancer

  2014cites this paper
• HKBU Institutional Repository

  2014cites this paper
• A New Approach to Cancer Therapy: The Tumor Microenvironment as Target

  2014cites this paper
• Cancer-testis gene expression profile in human melanoma cell lines

  2014cites this paper
• Exploring alternative cytotoxic strategies for cancer treatment

  2014cites this paper
• Manipulating the Tumor Microenvironment Ex Vivo for Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy

  2014cites this paper
• Improving the in vivo Persistence, Distribution and Function of Cytotoxic T Lymphocytes by Inhibiting the Tumor Immunosuppressive Microenvironment

  2013cites this paper
• GENERATION OF TUMOR-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FROM PERIPHERAL BLOOD OF COLORECTAL CANCER PATIENTS FOR ADOPTIVE T-CELL TRANSFER

  2013cites this paper
• Lentiviral vectors: a versatile tool to fight cancer.

  2013cites this paper
• Treatment patterns of dermatological disorders in the private health care sector of Namibia

  2013cites this paper
• Myeloid Derived Suppressor Cells: Subsets, Expansion, and Role in Cancer Progression

  2012cites this paper
• The immune system: endogenous anticancer mechanism.

  2012cites this paper
• Novel therapies for the treatment of metastatic melanoma.

  2012cites this paper
• Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells.

  2012cites this paper
• HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients.

  2012cites this paper
• Exploiting the Interplay between Innate and Adaptive Immunity to Improve Immunotherapeutic Strategies for Epstein-Barr-Virus-Driven Disorders

  2012cites this paper
• Central and effector memory CD4 and CD8 T-cell responses to tumor-associated antigens.

  2012cites this paper
• Evaluating elastic properties of heterogeneous soft tissue by surface acoustic waves detected by phase-sensitive optical coherence tomography.

  2012cites this paper
• Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.

  2012cites this paper
• Lessons from Cancer Immunoediting in Cutaneous Melanoma

  2012cites this paper
• Role of CD44 in lymphokine-activated killer cell-mediated killing of melanoma

  2012cites this paper
• Chimeric Antigen Receptor Engineered T cells for adoptive immunotherapy of Prostate Cancer

  2012cites this paper
• Characterization and Comparison of ‘Standard’ and ‘Young’ Tumour‐Infiltrating Lymphocytes for Adoptive Cell Therapy at a Danish Translational Research Institution

  2012cites this paper
• Tumor escape after immunotherapy: implication of hla class i expression in melanoma and bladder tumors

  2011cites this paper
• Roles of the immune system in skin cancer

  2011cites this paper
• Chemocentric Chemoimmunotherapy: A New Concept in Melanoma Immunotherapy

  2011cites this paper